Cuorips Inc. (4894.T)
JPY 7680.0
(-9.11%)
JPY 7680.0
(-9.11%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 598.11 Million JPY | 26.87% |
| 2022 | 471.44 Million JPY | 22.8% |
| 2021 | 383.91 Million JPY | 36.15% |
| 2020 | 281.97 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 177.68 Million JPY | 34.5% |
| 2023 FY | 598.11 Million JPY | 26.87% |
| 2023 Q4 | 132.1 Million JPY | -23.04% |
| 2023 Q3 | 171.65 Million JPY | 7.63% |
| 2023 Q1 | 134.87 Million JPY | 25.19% |
| 2023 Q2 | 159.48 Million JPY | 18.25% |
| 2022 FY | 471.44 Million JPY | 22.8% |
| 2022 Q4 | 107.73 Million JPY | 0.0% |
| 2021 FY | 383.91 Million JPY | 36.15% |
| 2020 FY | 281.97 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | 53.435% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -3.693% |
| GNI Group Ltd. | 9.32 Billion JPY | 93.584% |
| Linical Co., Ltd. | 2.7 Billion JPY | 77.89% |
| Trans Genic Inc. | 2.15 Billion JPY | 72.307% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 59.889% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 80.524% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 67.791% |
| AnGes, Inc. | 8.9 Billion JPY | 93.281% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | 36.578% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 96.883% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -44.826% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | 38.678% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 76.705% |
| CanBas Co., Ltd. | 278 Million JPY | -115.15% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | 47.604% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 67.099% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 62.705% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 74.806% |
| PeptiDream Inc. | 9.68 Billion JPY | 93.826% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 69.493% |
| Ribomic Inc. | 1.1 Billion JPY | 45.906% |
| SanBio Company Limited | 4.53 Billion JPY | 86.823% |
| Healios K.K. | 3.48 Billion JPY | 82.847% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | 48.203% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 55.179% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 57.383% |
| StemRIM | 2.07 Billion JPY | 71.189% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 69.538% |
| FunPep Company Limited | 313.82 Million JPY | -90.592% |
| Kringle Pharma, Inc. | 958.01 Million JPY | 37.567% |
| Stella Pharma Corporation | 963.98 Million JPY | 37.954% |
| TMS Co., Ltd. | 943.25 Million JPY | 36.59% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | 45.124% |
| K Pharma,Inc. | 543.94 Million JPY | -9.96% |
| Takara Bio Inc. | 23.9 Billion JPY | 97.498% |
| ReproCELL Incorporated | 1.51 Billion JPY | 60.495% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | 49.483% |
| StemCell Institute Inc. | 1.16 Billion JPY | 48.532% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 60.709% |
| CellSeed Inc. | 804.93 Million JPY | 25.693% |